Table 1:

Demographics characteristics of study participants. Values are mean ± standards deviation or n (%).

	CGRP-receptor mAb-group	CGRP mAb-group	p value
n	29 • n = 9: 70 mg• n = 20: 140 mg	30• n = 20: galcanezumab• n = 10: fremanezumab
Age (years)	49.3 ± 12.9	49.2 ± 10.1	0.99
Sex (female)	25 (89.7%)	29 (96.7%)	0.35
Chronic migraine	20 (69.0%)	22 (73.3%)	0.78
With aura	17 (58.6%)	18 (60.0%)	>0.999
Years since first manifestation of migraine	28.7 ± 11.3	30.8 ± 11.8	0.50
Months of treatment before discontinuation	9.8 ± 1.3	9.5 ± 0.8	0.41